In renal cell carcinoma (RCC), KLK6 expression varies by subtype and tends to be elevated in more aggressive tumors, correlating with advanced staging and poorer survival, making it a potential biomarker for RCC subtyping [24,25]. This evidence concerns the gene KLK6 and hereditary clear cell renal cell carcinoma.